Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ataxin 8 opposite strand long non-coding RNA (ATXN8OS) is an antisense transcript located on chromosome 13q21. It is classified as a long non-coding RNA (lncRNA) and does not encode a protein. ATXN8OS has pleiotropic roles in normal physiology and disease. In spinocerebellar ataxia type 8 (SCA8), expanded trinucleotide repeats in ATXN8OS are pathogenic, leading to neurodegeneration[2]. In cancer, ATXN8OS is overexpressed and acts via competing endogenous RNA (ceRNA) mechanisms, notably by sequestering microRNAs such as miR-204, which results in enhanced cell proliferation and invasion in breast cancer[1]. In gliomas, ATXN8OS suppresses temozolomide resistance by promoting ferroptosis through the ADAR/GLS2 pathway[3]. Functionally, ATXN8OS is implicated in cell cycle regulation and can serve as a prognostic biomarker in cancer. There are currently no drugs directly targeting ATXN8OS, but its molecular interactions offer promising therapeutic and diagnostic opportunities.
Acts as a ceRNA by sequestering specific microRNAs (notably miR-204) to regulate downstream targets; Regulates chemoresistance and ferroptosis in glioma through ADAR/GLS2 pathway
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ataxin 8 opposite strand long non-coding RNA (ATXN8OS).